Evidence map›Paper›PMID 34072332›Full record

ReviewViruses2021

Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses.

Charles J Russell, Julia L Hurwitz

Open access · goldAbstract readReview
In one paragraph

Review in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Optical Control of Mononegavirus Gene Expression and Replication.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Charles J RussellDepartment of Infectious Diseases, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-3678, USA.ORCID 0000-0001-5683-3990
Julia L HurwitzDepartment of Infectious Diseases, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-3678, USA.
St. Jude Children's Research Hospital · US

Funding

Recombinant Sendai Virus as Novel Paramyxovirus VaccineP01AI054955 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI PORTNER, ALLEN · 2004 to 2008
$3.7M
Influence of maternal antibodies on a Sendai virus-vectored RSV vaccineR01AI088729 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI DEVINCENZO, JOHN P., HURWITZ, JULIA L · 2010 to 2014
$3.0M
NIAID NIH HHS P01 AI054955NIAID NIH HHS R01 AI088729
6 · The paper itself

Abstract

Human respiratory syncytial virus (HRSV), human metapneumovirus (HMPV), and human parainfluenza viruses (HPIVs) are leading causes of respiratory disease in young children, the elderly, and individuals of all ages with immunosuppression. Vaccination strategies against these pneumoviruses and paramyxoviruses are vast in number, yet no licensed vaccines are available. Here, we review development of Sendai virus (SeV), a versatile pediatric vaccine that can (a) serve as a Jennerian vaccine against HPIV1, (b) serve as a recombinant vaccine against HRSV, HPIV2, HPIV3, and HMPV, (c) accommodate foreign genes for viral glycoproteins in multiple intergenic positions, (d) induce durable, mucosal, B-cell, and T-cell immune responses without enhanced immunopathology, (e) protect cotton rats, African green monkeys, and chimpanzees from infection, and (f) be formulated into a vaccine cocktail. Clinical phase I safety trials of SeV have been completed in adults and 3-6-year-old children. Clinical testing of SeVRSV, an HRSV fusion (F) glycoprotein gene recombinant, has also been completed in adults. Positive results from these studies, and collaborative efforts with the National Institutes of Health and the Serum Institute of India assist advanced development of SeV-based vaccines. Prospects are now good for vaccine successes in infants and consequent protection against serious viral disease.

Indexed as

AnimalsAntibodies, ViralClinical Trials as TopicGenetic VectorsMiceParainfluenza Virus 1, HumanRespiratory Syncytial Virus, HumanRespiratory Tract InfectionsSendai virusVaccines, SyntheticViral Envelope ProteinsViral VaccinesVirusesAntibodies, ViralVaccines, SyntheticViral Envelope ProteinsViral Vaccinesattachment proteinenvelope glycoproteinfusion glycoproteinHRSVparainfluenza virusparamyxoviruspneumovirusvaccine vector

Identifiers

PMID34072332
PMCPMC8230104
OpenAlexW3165174463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.